Systemic Lupus Erythematosus (SLE) Disease
Vilacto Bio™ treats a wide range of inflammatory abnormalities, inflammation related disorders (both acute and chronic) and is well within the capacity of our patented properties (Lactoactive®).
We have already overcome notorious healing challenges for some of those concerns, like such wounds, psoriasis, vitiligo and autoimmune related skin conditions. Our products are currently available on the market as Vilact®. Our aim is to develop new drugs and treatment based on our current treatments to help more people suffering from debilitating skin conditions.
Fast Facts in the USA:
More than 90% of lupus sufferers are women – mostly young women between the ages of 15 to 44.
1 to 1.5 million Americans are living with some form of lupus.
The mean annual total costs (combining direct costs and productivity costs for subjects of employment age) was $20,924 in 2008.
The North American market is growing at a tremendous 24.7% compound annual growth rate (CAGR).
Approximately $10,229 per patient per year in the SLE cohort relative to the non-SLE cohort is driven largely by inpatient hospitalization costs (p is less than 0.001).
Global Fast Facts:
Prevalence of systemic lupus erythematosus (SLE) in the population is 20 – 150 cases per 100,000.
The disease is 2 to 4 times more frequent, and more severe, among nonwhite populations around the world and tends to be more severe in men and in pediatric and late-onset lupus.
Lupus raises mortality by 67%; with young adults at highest risk.
Mean annual expenditures for persons with SLE were $12,238 greater than those for persons without SLE.
The global market for drugs to treat systemic lupus erythematosus (SLE) is expected to grow to $2.6 billion by 2018, with a five-year compound annual growth rate (CAGR) of 22.4% from 2013.
References
1. Drugs for Treating Systemic Lupus Erythematosus: Global Markets( PHM159A )
2. Nature Clinical Practice RheumatologyISSN: 1745-8382EISSN: 1745-8390, 2016 Macmillan Publishers Limited, part of Springer Nature.
3. Garris et al.; licensee BioMed Central. 2015.The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims
4. Erin E et al; The global burden of SLE: prevalence, health disparities, and socioeconomic impact.Nature Reviews Rheumatology 12, 605–620 (2016) doi:10.1038/nrrheum.2016.137